Nicholas Lydon
PhD
Co-Founder, Blueprint Medicines
👥Biography 个人简介
Nicholas Lydon was among the Novartis scientists who discovered imatinib (STI-571/Gleevec) as a BCR-ABL tyrosine kinase inhibitor and collaborated with Brian Druker to demonstrate its dramatic activity in chronic myeloid leukemia. His pharmaceutical chemistry expertise was essential in converting early lead compounds into the drug that transformed CML from a fatal to a manageable disease. He subsequently co-founded Blueprint Medicines to apply similar principles to other oncogenic kinases. He received the Lasker Award in 2009 and the Breakthrough Prize for transforming CML treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Nicholas Lydon 的研究动态
Follow Nicholas Lydon's research updates
留下邮箱，当我们发布与 Nicholas Lydon（Blueprint Medicines (formerly Novartis)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment